Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights
Provided By GlobeNewswire
Last update: Mar 31, 2025
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2024 operating and financial results and reviewed recent business highlights.
Read more at globenewswire.comNYSEARCA:CLDI (7/25/2025, 11:38:04 AM)
0.7084
-0.06 (-8%)
Find more stocks in the Stock Screener
CLDI Latest News and Analysis
